AVENGE BIO

Job Description – Research Associate

Responsibilities:

- Support internal research efforts including mammalian cell culture to enable preclinical, toxicology, and clinical studies, including candidate selection/discovery, clone selection, cell line maintenance
- Collaborate closely with other research groups and project teams to achieve program goals
- Deliver a variety of assay for various therapeutic programs and service demands for colleagues within deadlines
- Make detailed observations, analyze data, and interpret results
- Draft SOPs, and present data in various formats.
- Establish and participate in discussions to optimize protocols, tools, and/or new methods for project advancement.
- Write detailed experimental protocols, maintain excellent records of experiments in laboratory notebooks
- Support lab functions-including, but not limited to restocking consumables, maintaining equipment and cleaning

Qualifications:

- BS or MS degree in biology, biochemical engineering, biology or relevant field, with previous of experience in biotech/pharma setting
- Previous experience with cell and gene therapy is a plus
- Proven experience in culturing different mammalian cell lines and aseptic techniques
- Experience with analytical methods for cell characterization such as ELISA, quantitative PCR and microscopy
- Experience with designing, executing and troubleshooting new protocols and assays.
- Attention to detail, critical analysis of data and troubleshooting abilities
- Good writing and communication skills; ability to understand and communicate scientific information
- Highly collaborative working style, and ability to adapt in a fast-paced environment
- Ability to work with minimal direction to meet objectives and timelines, adapting to changes and priorities in order to fulfill our mission

About Avenge Bio:

Avenge Bio, Inc. is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte™ platform. The LOCOcyte™ platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor. This initiates a robust, local and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. Avenge Bio was founded in 2019 based upon technology developed in

the laboratory of Omid Veiseh, Ph.D. and has an exclusive license from Rice University for this technology. To learn more, visit www.avengebio.com